Exhibit 99.2

Boston Scientific Contacts:
Milan Kofol, 508-650-8569, Investor Relations, Boston Scientific Corporation
Paul Donovan, 508-650-8541, Media Relations, Boston Scientific Corporation
Rubicon Medical Contact:
David Politis, Politis Communications, 801-523-3730(wk)/801-556-8184(cell),
dpolitis@politis.com

FOR IMMEDIATE RELEASE

         Boston Scientific and Rubicon Medical Announce CE Mark for the
                        Rubicon Embolic Protection Filter

             Three sizes approved for use in Saphenous Vein Grafts,
                     Native Coronaries and Carotid Arteries

NATICK, MA and SALT LAKE CITY, UT - April 14, 2005 - Boston Scientific
Corporation (NYSE: BSX) and Rubicon Medical Corporation (OTC BB: RMDC) today
announced that Rubicon has received CE Mark for its Rubicon Filter(TM). The
Rubicon Filter is an embolic protection system that traps and removes debris
that may be dislodged during interventional procedures. It has been cleared for
commercialization in three indications - saphenous vein grafts (SVG), native
coronary arteries and carotid arteries - as well as in three sizes: 4mm, 5mm and
6mm filters. The Rubicon Filter has not been approved for sale in the United
States.

"This is a big day for Rubicon Medical as we have been working toward these
goals for some time," said Linder. "The Rubicon Filter performed marvelously in
both native and SVG procedures, as well as in carotid applications. We have been
working diligently in preparation for this approval, and I would like to
personally thank all Rubicon Medical employees for their hard work and diligence
in achieving this important milestone."

"The Rubicon Filter is a potential paradigm-shifting technology due to its low
profile and ease of use," said Paul LaViolette, Boston Scientific Chief
Operating Officer. "We look forward to marketing and selling the Rubicon Filter
in markets where CE Mark clearance is accepted."

Rubicon Medical conducted two parallel clinical studies in Europe in support of
CE Mark for the Rubicon Filter. The RULE-SVG study included 54 patients with
either saphenous vein graft disease or coronary artery disease in the native
coronary arteries, including a number of high-risk stenting procedures. These
procedures were performed by leading cardiologists at hospitals in Germany and
Italy, with many of the studies conducted by Prof. Eberhard Grube, M.D., Chief
of Interventional Cardiology at Heart Center Siegburg in Siegburg, Germany.

In Rubicon's RULE-Carotid study, the Rubicon Filter was used in 60 procedures
with patients suffering from significantly blocked carotid arteries, the main
vessels in the neck, which feed blood directly to the brain. The procedures were
performed by leading cardiologists at hospitals in Germany, with Prof. Joachim
Schofer, M.D., Co-Founder of the Center of Cardiology and Vascular Intervention
in Hamburg, Germany, serving as the Principal Investigator.

<PAGE>

The Role of the Rubicon Filter as an Embolic Protection Device

To treat patients who have blood vessels partially or fully occluded (blocked)
with plaque buildup on the vessel walls, surgeons will often utilize a small
wire mesh tube known as a stent to prop open the target vein or artery. When
used in conjunction with a stenting procedure, the Rubicon Filter is maneuvered
into place and deployed downstream from the blockage prior to the delivery and
opening of the stent, with the goal of allowing surgeons to capture and remove
dislodged plaque from the blood vessel during and after the stenting procedure.
Studies have identified such dislodged plaque (or embolic material) as a
potential cause of heart attacks, stroke, kidney failure and death.

About Boston Scientific
-----------------------
Boston Scientific is a worldwide developer, manufacturer and marketer of medical
devices whose products are used in a broad range of interventional medical
specialties. For more information, please visit:
http://www.bostonscientific.com.

About Rubicon Medical
---------------------
Rubicon Medical Corporation (www.rubiconmed.com) is a Salt Lake City-based
developer and manufacturer of interventional vascular medical devices and
products. The company focuses on minimally invasive endovascular techniques and
products that are safer and more cost effective than surgery.

Forward Looking Statements: All forward-looking statements in this release are
based upon information available to the companies on the date of this release.
Any forward-looking statements involve risks and uncertainties, including those
risks and uncertainties described in each company's filings with the Securities
and Exchange Commission, that could cause actual events or results to differ
materially from the events or results described in the forward-looking
statements, whether as a result of new information, future events or otherwise.
Rubicon's Rubicon Filter has not yet been approved for sale in the U.S., and no
assurance exists that such approval will be obtained. Likewise, there are no
guarantees that Rubicon Filter sales and marketing efforts will be successful in
regions where CE Mark clearance is accepted. Readers should not place undue
reliance on these forward-looking statements.

                                      # # #